Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Laminectomy alone versus fusion for grade 1 lumbar spondylolisthesis in 426 patients from the prospective Quality Outcomes Database
Chan, Andrew K. , Bisson, Erica F. , Bydon, Mohamad , Glassman, Steven D. , Foley, Kevin T. , Potts, Eric A. , Shaffrey, Christopher I. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Park, Paul , Wang, Michael Y. , Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L. , Virk, Michael S., Kerezoudis, Panagiotis , Chotai, Silky , DiGiorgio, Anthony M. , Haid, Regis W., Mummaneni, Praveen V. , Virk, Michael S.

Mayo Clinic

Journal of Neurosurgery: Spine | February 20, 2019 | Volume: 30 | Issue: 2 | Pages: 234-241

10.3171/2018.8.spine17913 | PMID 30544348 Get It

OBJECTIVEThe AANS launched the Quality Outcomes Database (QOD), a prospective longitudinal registry that includes demographic, clinical, and patient-reported outcome (PRO) data to measure the safety and quality of spine surgery. Registry data offer “real-world” insights into the utility of spinal fusion and decompression surgery for lumbar spondylolisthesis. Using the QOD, the authors compared the initial 12-month outcome data for patients undergoing fusion and those undergoing laminectomy alone for grade 1 degenerative lumbar spondylolisthesis.METHODSData from 12 top enrolling sites were analyzed and 426 patients undergoing elective single-level spine surgery for degenerative grade 1 lumbar spondylolisthesis were found. Baseline, 3-month, and 12-month follow-up data were collected and compared, including baseline clinical characteristics, readmission rates, reoperation rates, and PROs. The PROs included Oswestry Disability Index (ODI), back and leg pain numeric rating scale (NRS) scores, and EuroQol–5 Dimensions health survey (EQ-5D) results.RESULTSA total of 342 (80.3%) patients underwent fusion, with the remaining 84 (19.7%) undergoing decompression alone. The fusion cohort was younger (60.7 vs 69.9 years, p < 0.001), had a higher mean body mass index (31.0 vs 28.4, p < 0.001), and had a greater proportion of patients with back pain as a major component of their initial presentation (88.0% vs 60.7%, p < 0.001). There were no differences in 12-month reoperation rate (4.4% vs 6.0%, p = 0.93) and 3-month readmission rates (3.5% vs 1.2%, p = 0.45). At 12 months, both cohorts improved significantly with regard to ODI, NRS back and leg pain, and EQ-5D (p < 0.001, all comparisons). In adjusted analysis, fusion procedures were associated with superior 12-month ODI (β −4.79, 95% CI −9.28 to −0.31; p = 0.04).CONCLUSIONSSurgery for grade 1 lumbar spondylolisthesis—regardless of treatment strategy—was associated with significant improvements in disability, back and leg pain, and quality of life at 12 months. When adjusting for covariates, fusion surgery was associated with superior ODI at 12 months. Although fusion procedures were associated with a lower rate of reoperation, there was no statistically significant difference at 12 months. Further study must be undertaken to assess the durability of either surgical strategy in longer-term follow-up.
Atrial fibrillation ablation in practice: assessing CABANA generalizability
Kent, David M. , Piccini, Jonathan P. , Packer, Douglas L. , Shah, Nilay D. , Yao, Xiaoxi , Noseworthy, Peter A. , Gersh, Bernard J. , Kent, David M

Mayo Clinic

European Heart Journal | February 17, 2019 | Volume: 40 | Issue: 16 | Pages: 1257-1264

10.1093/eurheartj/ehz085 | PMID 30875424 Get It

Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity
Zhang, Yong‐Jie , Guo, Lin , Gonzales, Patrick , Gendron, Tania F. , Wu, Yanwei , Jansen‐West, Karen , O’Raw, Aliesha D. , Pickles, Sarah , Prudencio, Mercedes , Carlomagno, Yari , Gachechiladze, Mariam A. , Tian, Ruilin , Chew, Jeannie , DeTure, Michael , Lin, Wen-Lang, Tong, Jimei, Daughrity, Lillian M. , Yue, Mei, Song, Yuping , Andersen, Jonathan W. , Castanedes‐Casey, Monica , Kurti, Aishe, Antognetti, Giovanna, McCampbell, Alexander , Rademakers, Rosa , Oskarsson, Björn , Kampmann, Martin , Ward, Michael E. , Fryer, John Denis , Link, Christopher D. , Shorter, James , Petrucelli, Leonard , Gonzales, Patrick K , Pickles, Sarah R , Chew, Jeannie , DeTure, Michael , Daughrity, Lillian M , Castanedes-Casey, Monica , McCampbell, Alexander , Rademakers, Rosa , Oskarsson, Björn , Dickson, Dennis W , Kampmann, Martin , Ward, Michael E , Shorter, James , Petrucelli, Leonard , Zhang, Yong-Jie , Prudencio, Mercedes , O'Raw, Aliesha , Gendron, Tania F , Guo, Lin , Ludwig, Connor , Datta, Abhishek, Dickson, Dennis W.

Mayo Clinic

Science | February 15, 2019 | Volume: 363 | Issue: 6428 | Pages: No page available

10.1126/science.aav2606 | PMID 30765536 Get It

How dipeptide repeats cause pathology A repeat expansion in the chromosome 9 open reading frame 72 ( C9orf72 ) gene is the most common known cause of two neurodegenerative diseases: frontotemporal dementia and amyotrophic lateral sclerosis. This expansion leads to the abnormal production of proteins of repeating dipeptides, but their contribution to disease pathogenesis remains unclear. Zhang et al. engineered a mouse model to study the consequences of one of these dipeptides—prolinearginine dipeptide repeat protein, poly(PR)—in the brain. They found that poly(PR) caused neuron loss as well as motor and memory impairments. These detrimental effects resulted from poly(PR)-induced perturbation of heterochromatin function, a tightly packed form of DNA that represses gene expression. Science , this issue p. eaav2606
Prescribing Practices for Patients With Borderline Personality Disorder During Psychiatric Hospitalizations
Romanowicz, Magdalena , Schak, Kathryn M. , Voort, Jennifer L. Vande , Leung, Jonathan G. , Palmer, Brian A. , Vande Voort, Jennifer L., Larrabee, Beth R. , Leung, Jonathan G

Mayo Clinic

Journal of Personality Disorders | February 11, 2019 | Volume: 34 | Issue: 6 | Pages: 736-749

10.1521/pedi_2019_33_405 | PMID 30742548 Get It

This study aimed to understand prescribing practices during acute psychiatric hospitalization in a large cohort of patients (N = 569) with borderline personality disorder (BPD) at a tertiary care psychiatry unit from January 1, 2013, through January 1, 2015. The mean number of hospitalizations per patient was 1.5 (range, 1–7). The odds of being prescribed antidepressants, antipsychotics, mood stabilizers, hypnotics, or anxiolytics were higher at discharge than at admission. The rate of psychotropic prescriptions was also higher at discharge than at admission (incidence rate ratio, 1.9). This pattern was true for the combined psychotropic and nonpsychotropic (“medical”) prescriptions. Further guidelines are needed regarding optimal psychosocial, medical, and psychopharmacological care of patients with BPD during acute psychiatric hospitalizations.
Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma
Kohlenberg, Jacob , Welch, Brian T. , Hamidi, Oksana , Callstrom, Matthew R. , Morris, Jonathan M. , Welch, Brian, Callstrom, Matthew, Hamidi, Oksana , Morris, Jonathan , Šprung, Juraj , Bancos, Irina , Young, William F.

Mayo Clinic

Cancers | February 7, 2019 | Volume: 11 | Issue: 2 | Pages: 195

10.3390/cancers11020195 | PMID 30736463 Get It

Metastatic pheochromocytoma and paraganglioma (PPGL) are incurable neuroendocrine tumors. The goals of treatment include palliating symptoms and reducing tumor burden. Little is known about the use of radiofrequency ablation (RFA), cryoablation (CRYO), and percutaneous ethanol injection (PEI) to treat metastatic PPGL. We performed a retrospective study of patients age 17 years and older with metastatic PPGL who were treated with ablative therapy at Mayo Clinic, USA, between June 14, 1999 and November 14, 2017. Our outcomes measures were radiographic response, procedure-related complications, and symptomatic improvement. Thirty-one patients with metastatic PPGL had 123 lesions treated during 42 RFA, 23 CRYO, and 4 PEI procedures. The median duration of follow-up was 60 months (range, 0–163 months) for non-deceased patients. Radiographic local control was achieved in 69/80 (86%) lesions. Improvement in metastasis-related pain or symptoms of catecholamine excess was achieved in 12/13 (92%) procedures. Thirty-three (67%) procedures had no known complications. Clavien-Dindo Grade I, II, IV, and V complications occurred after 7 (14%), 7 (14%), 1 (2%), and 1 (2%) of the procedures, respectively. In patients with metastatic PPGL, ablative therapy can effectively achieve local control and palliate symptoms.
Association of Apolipoprotein E With Intracerebral Hemorrhage Risk by Race/Ethnicity
Marini, Sandro, Crawford, Katherine, Morotti, Andrea, Lee, Myung J., Pezzini, Alessandro, Moomaw, Charles J., Flaherty, Matthew L., Montaner, Joan, Roquer, Jaume, Jimenez-Conde, Jordi, Giralt-Steinhauer, Eva, Elosua, Roberto, Cuadrado-Godia, Elisa, Soriano-Tarraga, Carolina, Slowik, Agnieszka, Jagiella, Jeremiasz M., Pera, Joanna, Urbanik, Andrzej, Pichler, Alexander, Hansen, Björn M., McCauley, Jacob L., Tirschwell, David L., Selim, Magdy, Brown, Devin L., Silliman, Scott L., Worrall, Bradford B., Meschia, James F., Kidwell, Chelsea S., Testai, Fernando D., Kittner, Steven J., Schmidt, Helena, Enzinger, Christian, Deary, Ian J., Rannikmae, Kristiina, Samarasekera, Neshika, Salman, Rustam Al-Shahi, Sudlow, Catherine L., Klijn, Catharina J. M., Nieuwenhuizen, Koen M. van, Fernandez-Cadenas, Israel, Delgado, Pilar, Norrving, Bo, Lindgren, Arne, Goldstein, Joshua N., Viswanathan, Anand, Greenberg, Steven M., Falcone, Guido J., Biffi, Alessandro, Langefeld, Carl D., Woo, Daniel, Rosand, Jonathan, Anderson, Christopher D., Hardy, John , Benjamin, Emelia J. , Montaner, Joan , Rotter, Jerome I. , Seshadri, Sudha , Anderson, Christopher D. , Lubitz, Steven A. , Sudlow, Cathie , Rannikmäe, Kristiina , James, Michael L. , Testai, Fernando D. , Maguire, Jane , Brown, Devin L. , Tirschwell, David , Hansen, Björn M. , Elosúa, Roberto , Cuadrado‐Godia, Elisa , Soriano‐Tárraga, Carolina , Nieuwenhuizen, Koen M. van , Klijn, Catharina J.M. , Samarasekera, Neshika , Salman, Rustam Al‐Shahi , Pezzini, Alessandro , Delgado, Pilar , Lee, Chaeyoung , McCauley, Jacob L. , Marini, Sandro , Chen, Christopher , Bersano, Anna , van Nieuwenhuizen, Koen M , Seshadri, Sudha , Hardy, John , Montaner, Joan , Benjamin, Emelia J , Lubitz, Steven A , Rotter, Jerome I , Pezzini, Alessandro , Crawford, Katherine, Morotti, Andrea, Lee, Myung J., Moomaw, Charles J., Flaherty, Matthew L., Roquer, Jaume, Jimenez-Conde, Jordi, Giralt-Steinhauer, Eva, Slowik, Agnieszka, Jagiella, Jeremiasz M., Pera, Joanna, Urbanik, Andrzej, Pichler, Alexander, Hansen, Björn M., Selim, Magdy, Brown, Devin L., Silliman, Scott L., Worrall, Bradford B., Meschia, James F., Kidwell, Chelsea S., Kittner, Steven J., Schmidt, Helena, Enzinger, Christian, Deary, Ian J., Salman, Rustam Al-Shahi, Fernandez-Cadenas, Israel, Delgado, Pilar, Norrving, Bo, Lindgren, Arne, Goldstein, Joshua N., Viswanathan, Anand, Greenberg, Steven M., Falcone, Guido J., Biffi, Alessandro, Langefeld, Carl D., Woo, Daniel, Rosand, Jonathan, Anderson, Christopher D., Al-Shahi Salman, Rustam , Bersano, Anna , Testai, Fernando D , McCauley, Jacob L

Mayo Clinic

JAMA Neurology | February 6, 2019 | Volume: 76 | Issue: 4 | Pages: 480

10.1001/jamaneurol.2018.4519 | PMID 30726504 Get It

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
Bartlett, Nancy L. , Smith, Sonali M. , Leonard, John P. , Evens, Andrew M. , Friedberg, Jonathan W. , Bartlett, Nancy L , Evens, Andrew M , Hsi, Eric D. , Li, Hongli , Nixon, Andrew B. , Schöder, Heiko , LeBlanc, Michael , Kahl, Brad S. , Scott, David W. , Rimsza, Lisa M.

Mayo Clinic

Blood | February 6, 2019 | Volume: 133 | Issue: 16 | Pages: 1762-1765

10.1182/blood-2018-08-870915 | PMID 30723079 Get It

Abstract Serum soluble chemokines/cytokines produced by Hodgkin cells and the tumor microenvironment might be of value as biomarkers in classic Hodgkin lymphoma (cHL). We assessed serum thymus and activation-related chemokine (TARC), macrophage-derived chemokine (MDC), interleukin-10 (IL-10), and soluble CD163 (sCD163) levels at baseline, time of interim fluorodeoxyglucose positron emission tomography (PET), and after therapy in cHL patients treated on S0816, an intergroup phase 2 response-adapted study evaluating escalated therapy for interim PET (PET2)–positive patients (www.clinicaltrials.gov #NCT00822120). Epstein-Barr virus (EBV) status was assessed, and 559 serum samples were evaluated for TARC, MDC, IL-10, and sCD163 by immunoassay. EBV positivity correlated with higher sCD163 and IL-10 levels but lower TARC levels. While baseline biomarker levels were not associated with outcome, sCD163 levels at the time of PET2 were associated with favorable progression-free survival (PFS), adjusting for PET2 status. After therapy TARC, MDC, and IL-10 correlated with PFS and overall survival (OS) on univariable analysis, which remained significant adjusting for international prognostic score. When also adjusting for end-of-therapy PET results, TARC and IL-10 remained significantly associated with shorter PFS and OS. Exploratory analysis in PET2-negative patients showed that elevated posttherapy TARC and IL-10 levels were associated with PFS. Serum cytokine levels correlate with outcome in cHL and should be investigated further in risk-adapted cHL trials.
Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study
Mutsaerts, Henk , Mirza, Saira Saeed , Petr, Jan , Thomas, David L. , Cash, David M. , Bocchetta, Martina , Metcalfe, Arron W.S. , Shirzadi, Zahra , Robertson, Andrew D. , Tartaglia, Maria Carmela , Mitchell, Sara, Freedman, Morris , Tang‐Wai, David F. , Keren, Ron , Laforce, Robert , Tagliavini, Fabrizio , Borroni, Barbara , Galimberti, Daniela , Rowe, James B. , Graff, Caroline , Frisoni, Giovanni B. , Finger, Elizabeth , Sorbi, Sandro , Mendonça, Alexandre de , Rohrer, Jonathan D. , MacIntosh, Bradley J. , (GENFI), GENetic Frontotemporal dementia Initiative, Andersson, Christin, Archetti, Silvana, Arighi, Andrea , Benussi, Luisa , Binetti, Giuliano, Cosseddu, Maura , Dick, Katrina M., Fallström, Marie, Fenoglio, Chiara , Fumagalli, Giorgio, Gazzina, Stefano , Ghidoni, Roberta , Grisoli, Marina , Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Mead, Simon , Meeter, Lieke , Minkelen, Rick van , Öijerstedt, Linn , Ourselin, Sébastien , Padovani, Alessandro , Panman, Jessica , Pievani, Michela, Polito, Cristina , Premi, Enrico, Prioni, Sara, Rademakers, Rosa, Redaelli, Veronica, Rossi, Giacomina , Thonberg, Håkan, Tiraboschi, Pietro , Verdelho, Ana, Warren, Jason D. , Binetti, Giuliano, Fallström, Marie, Fumagalli, Giorgio, Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Pievani, Michela, Premi, Enrico, Prioni, Sara, Redaelli, Veronica, Verdelho, Ana, Binetti, Giuliano , Redaelli, Veronica , Prioni, Sara , Fumagalli, Giorgio , Frisoni, Giovanni B. , Finger, Elizabeth C. , Rowe, James B , Rohrer, Jonathan D , Padovani, Alessandro , Tartaglia, Maria Carmela , Cash, David M , Vita, Enrico De , Black, Sandra E. , Rogaeva, Ekaterina A. , Swieten, John C. van , Masellis, Mario , (GENFI), GENetic Frontotemporal dementia Initiative, Binetti, Giuliano, Fallström, Marie, Ferreira, Carlos , Fox, Nick C. , Fumagalli, Giorgio, Jelic, Vesna, Jiskoot, Lize C. , Lombardi, Gemma, Maruta, Carolina, Nacmias, Benedetta , Pievani, Michela, Premi, Enrico, Prioni, Sara, Rademakers, Rosa , Redaelli, Veronica, Rossor, Martin N. , Scarpini, Elio , Verdelho, Ana, Binetti, Giuliano, Fallström, Marie, Fumagalli, Giorgio, Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Pievani, Michela, Premi, Enrico, Prioni, Sara, Redaelli, Veronica, Verdelho, Ana, Galimberti, Daniela , de Mendonça, Alexandre , Bocchetta, Martina , Tiraboschi, Pietro , Laforce, Robert , Graff, Caroline , Borroni, Barbara

Mayo Clinic

Brain | February 2, 2019 | Volume: 142 | Issue: 4 | Pages: 1108-1120

10.1093/brain/awz039 | PMID 30847466 Get It

Abstract Genetic forms of frontotemporal dementia are most commonly due to mutations in three genes, C9orf72, GRN or MAPT, with presymptomatic carriers from families representing those at risk. While cerebral blood flow shows differences between frontotemporal dementia and other forms of dementia, there is limited evidence of its utility in presymptomatic stages of frontotemporal dementia. This study aimed to delineate the cerebral blood flow signature of presymptomatic, genetic frontotemporal dementia using a voxel-based approach. In the multicentre GENetic Frontotemporal dementia Initiative (GENFI) study, we investigated cross-sectional differences in arterial spin labelling MRI-based cerebral blood flow between presymptomatic C9orf72, GRN or MAPT mutation carriers (n = 107) and non-carriers (n = 113), using general linear mixed-effects models and voxel-based analyses. Cerebral blood flow within regions of interest derived from this model was then explored to identify differences between individual gene carrier groups and to estimate a timeframe for the expression of these differences. The voxel-based analysis revealed a significant inverse association between cerebral blood flow and the expected age of symptom onset in carriers, but not non-carriers. Regions included the bilateral insulae/orbitofrontal cortices, anterior cingulate/paracingulate gyri, and inferior parietal cortices, as well as the left middle temporal gyrus. For all bilateral regions, associations were greater on the right side. After correction for partial volume effects in a region of interest analysis, the results were found to be largely driven by the C9orf72 genetic subgroup. These cerebral blood flow differences first appeared approximately 12.5 years before the expected symptom onset determined on an individual basis. Cerebral blood flow was lower in presymptomatic mutation carriers closer to and beyond their expected age of symptom onset in key frontotemporal dementia signature regions. These results suggest that arterial spin labelling MRI may be a promising non-invasive imaging biomarker for the presymptomatic stages of genetic frontotemporal dementia.
Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable
Piccini, Jonathan P. , Xu, Haolin , Cox, Margueritte, Curtis, Anne B. , Fang, Margaret C. , McCabe, Pamela J. , Page, Robert L. , Turakhia, Mintu P. , Russo, Andrea M. , Knight, Bradley P. , Sidhu, Mandeep S. , Hurwitz, Jodie L. , Ellenbogen, Kenneth A. , Lewis, William R. , Knight, Bradley P , Turakhia, Mintu P , Matsouaka, Roland , Fonarow, Gregg C. , Butler, Javed , Desai, Nihar R. , Ellenbogen, Kenneth A

Mayo Clinic

Circulation | January 31, 2019 | Volume: 139 | Issue: 12 | Pages: 1497-1506

10.1161/circulationaha.118.035909 | PMID 30700141 Get It

Background: Efforts to improve prescription of oral anticoagulation (OAC) drugs in patients with atrial fibrillation have had limited success in improving guideline adherence. Methods: We evaluated adherence to the American College of Cardiology/American Heart Association performance measures for OAC in eligible patients with a CHA 2 DS 2 -VASc score ≥2 and trends in prescription over time in the American Heart Association’s Get With The Guidelines–AFIB (atrial fibrillation) registry. Adjusted associations with in-hospital outcomes were also determined. The cohort included 33 235 patients with a CHA 2 DS 2 -VASc score ≥2 who were admitted for atrial fibrillation and were enrolled at 115 sites between January 1, 2013, and September 31, 2017. Results: The median (25th, 75th percentile) age was 73 years (65, 81 years); 51% were female; and the median (25th, 75th percentile) CHA 2 DS 2 -VASc score was 4 (3, 5). At admission, 16 206 (59.5%) of 27 221 patients with a previous diagnosis of atrial fibrillation were taking OAC agents, and OAC drug use at admission was associated with a lower adjusted odds of in-hospital ischemic stroke (odds ratio, 0.38; 95% CI, 0.24–0.59; P <0.0001). At discharge, prescription of OAC in eligible patients (no contraindications) was 93.5% (n=25 499 of 27 270). In a sensitivity analysis, when excluding only strict contraindications (4.6%, n=1497 of 32 806), OAC prescription at discharge was 80.3%. OAC prescription at discharge was higher in those aged ≤75 years, men, those with heart failure, those with previous atrial fibrillation ablation, and those with rhythm control ( P <0.0001 for all). OAC use was lowest in Hispanic patients (90.2%, P <0.0001). Prescription of OAC at discharge in eligible patients improved over time from 79.9% to 96.6% ( P <0.0001). Conclusions: Among hospitals participating in the GWTG-AFIB quality improvement program, OAC prescription at discharge in eligible guideline-indicated patients increased significantly and improved consistently over time. These data confirm that high-level adherence to guideline-recommended stroke prevention is achievable.